Lead Product(s): Ziltivekimab
Therapeutic Area: Nephrology Product Name: COR-001
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
The RESCUE trial assessed the effect of once-monthly subcutaneous ziltivekimab on biomarkers of inflammation in patients with advanced CKD and elevated hsCRP.